HUM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Humana Inc (HUM) is not a strong buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock lacks clear positive momentum, has mixed analyst sentiment, and faces near-term uncertainties, particularly around its Medicare Advantage margins and 2026 guidance. While the company has shown revenue growth, its financial performance remains weak with negative net income and EPS. The absence of strong trading signals or significant positive catalysts further supports a hold recommendation.
The stock's MACD is positive at 2.618, indicating a bullish trend, but it is contracting. RSI is neutral at 41.045, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in price movement. The stock is trading near its support level (S1: 175.658) but below the pivot point (182.814), indicating limited upward momentum.
Humana's partnerships to enhance healthcare services, such as its collaboration with DAV to support veterans and its initiatives to improve cardiac care for Medicare Advantage members, could provide long-term benefits. Additionally, the company's revenue growth of 11.30% YoY is a positive indicator.
Analysts have significantly lowered price targets, reflecting concerns over Medicare Advantage margins, 2026 EPS guidance, and funding uncertainties. The company's recent public offering of $1 billion in subordinated notes to reduce financial leverage could signal financial strain. Negative net income and EPS further highlight financial challenges.
In Q4 2025, Humana reported an 11.30% YoY revenue increase to $32.515 billion. However, net income remained negative at -$796 million, though it improved 14.86% YoY. EPS also remained negative at -6.61, up 14.96% YoY. Gross margin was 0%, showing no improvement.
Analysts have lowered price targets significantly, with the most recent targets ranging from $146 to $250. Most firms maintain neutral or hold ratings, citing concerns over Medicare Advantage margins, 2026 guidance, and long-term visibility. While some analysts see long-term potential, the near-term outlook is cautious.
